, Volume 173, Issue 3–4, pp 234–241 | Cite as

Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity

  • A. C. ParrottEmail author



Not every tablet sold as “ecstasy” contains MDMA (3,4-methylenedioxymethamphetamine). The historical origins and evolution of this mismatch will be reviewed, in order to estimate the proportions of ecstasy tablets containing MDMA at different periods over the past 30 years.


Surveys into the pharmacological constituents of ecstasy tablets, dosage levels, and empirical reports of their perceived purity, provide the main data for this review.


During the 1980s and early 1990s there were few problems with the purity of ecstasy tablets, and the biochemical evidence shows that they nearly always contained MDMA. During the mid-1990s, the majority of ecstasy tablets continued to contain MDMA, while many others comprised MDA (3,4-methylenedioxyamphetamine), MDEA (3,4-methylenedioxyethylamphetamine), or amphetamine drug mixtures. However, a small proportion (4–20% according to survey, time and place), comprised non-amphetamine drugs such as caffeine, ephedrine, ketamine, paracetamol, or placebo. During the late 1990s, the proportion of ecstasy tablets containing MDMA increased to around 80–90%. The latest reports suggest that non-MDMA tablets are now very infrequent, with purity levels between 90% and 100%. Dosage levels of tablets are also highly variable, with low dose tablet often encountered during the mid-1990s, and high dose tablets now seen more frequently. The theoretical and practical implications of these findings will be debated.


The ecstasy purity problem was predominantly a phenomenon of the mid to late 1990s, when many tablets contained substances other than MDMA. Before and since then, the proportion of ecstasy tablets containing MDMA has been very high.


MDMA Ecstasy Amphetamine Stimulant Serotonin MDMA tablet purity MDMA tablet analysis 


  1. Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills. JAMA 284:2190PubMedGoogle Scholar
  2. Beck J (1990) The public health implications of MDMA use. In: Peroutka SJ (ed) Ecstasy: the clinical pharmacology and neurotoxicological effects of MDMA. Kluwer, BostonGoogle Scholar
  3. Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytrypamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153–160PubMedGoogle Scholar
  4. Cohen RS (1998) The love drug: marching to the beat of ecstasy. Haworth Medical Press, New York StateGoogle Scholar
  5. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531–1536CrossRefPubMedGoogle Scholar
  6. Cuomo MJ, Dyment PG, Gammino VM (1990) Increasing use of “ecstasy” (MDMA) and other hallucinogens on a college campus. J Am Coll Health 42:271–274Google Scholar
  7. Curran V (2000) Is MDMA (“ecstasy”) neurotoxic in humans? An overview of evidence and methodological problems in research. Neuropsychobiology 42:34–41PubMedGoogle Scholar
  8. Davison D, Parrott AC (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:91–97CrossRefGoogle Scholar
  9. Dowling GP (1990) Human deaths and toxic reactions attributed to MDMA and MDEA. In: Peroutka SJ (ed) Ecstasy: the clinical pharmacology and neurotoxicological effects of MDMA. Kluwer, BostonGoogle Scholar
  10. Dye C (1982a) MDA/MDM: the chemical pursuit of ecstasy. Do it Now Publications, Phoenix, Ariz.Google Scholar
  11. Dye C (1982b) XTC: the chemical pursuit of pleasure. Drug Survival News 10:8–9Google Scholar
  12. Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A, (2000) MDMA (“ecstasy”) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385–1390CrossRefPubMedGoogle Scholar
  13. Fox H, Parrott AC, Turner JJD (2001) Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. J Psychopharmacol 15:273–281PubMedGoogle Scholar
  14. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (“ecstasy”) polydrug users. Psychopharmacology 162:203–214CrossRefPubMedGoogle Scholar
  15. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 119:247–260PubMedGoogle Scholar
  16. Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev (in press)Google Scholar
  17. Hammersley R, Ditton J, Smith I, Short E (1999) Patterns of ecstasy use by drug users. Br J Criminol 39:625–647CrossRefGoogle Scholar
  18. Handy C, Pates R, Barrowcliff A (1998) Drug use in South Wales: who uses ecstasy anyway? J Subst Misuse 3:82–88Google Scholar
  19. Hansen D, Maycock B, Lower T (2001) “Weddings, parties, anything...”, a qualitative analysis of ecstasy use in Perth, Western Australia. Int J Drug Policy 12:181–199CrossRefPubMedGoogle Scholar
  20. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539–553PubMedGoogle Scholar
  21. Henry JA, Jeffries KJ, Dawling S (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 340:384–387PubMedGoogle Scholar
  22. Jackson B, Reed A (1970) Another abusable amphetamine. JAMA 211:830CrossRefGoogle Scholar
  23. King LA (2000) Was it MDMA? Neuropsychobiology 42:45–46Google Scholar
  24. McCann UD, Eligulashvili V, Ricaurte GA (2000) (±) 3,4-methylenedioxymethamphetamine (“ecstasy”)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42:11–16Google Scholar
  25. McDowell DM, Kleber HD (1994) MDMA: its history and Pharmacology. Psychiatr Ann 24:127–130Google Scholar
  26. Milroy CM, Clark JC, Forrest ARW (1996) Pathology of deaths associated with “ecstasy” and “eve”. J Clin Pathol 49:149–153PubMedGoogle Scholar
  27. Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230–248PubMedGoogle Scholar
  28. Palenicek T, Fiserova M, Kubu P (2002) Test of ecstasy tablets in Czech Republic—quantitative analysis. Adiktologie 1:70–71Google Scholar
  29. Parrott AC (2000) Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioral indices of change. Neuropsychobiology 42:17–24PubMedGoogle Scholar
  30. Parrott AC (2001) Human psychopharmacology of ecstasy/MDMA: a review of fifteen years of empirical research. Hum Psychopharmacol 16:557–578Google Scholar
  31. Parrott AC (2002a) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844CrossRefGoogle Scholar
  32. Parrott (2002b) Tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. Psychobiol Newsletter (Winter):16–17Google Scholar
  33. Parrott AC, Sisk E, Turner J (2000) Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug Alcohol Depend 60:105–110PubMedGoogle Scholar
  34. Parrott AC, Milani R, Parmar R, Turner JJD (2001) Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77–82PubMedGoogle Scholar
  35. Parrott AC, Fox HC, Milani RM, Soar K, Turner JJD (2002) Polydrug use amongst recreational ecstasy users. Adiktologie 1:71Google Scholar
  36. Pedersen W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94:1695–1706CrossRefPubMedGoogle Scholar
  37. Peroutka SJ (1989) “Ecstasy”: a human neurotoxin? Arch Gen Psychiatry 46:191Google Scholar
  38. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277PubMedGoogle Scholar
  39. Polkis A, Mackell MA, Drake WK (1979) Fatal intoxication from 3,4-methylenedioxyamphetamine. J Forens Sci 24:70–75Google Scholar
  40. Pope HG, Ionescu-Pioggia M, Pope KW (2001) Drug use and lifestyle among college undergraduates: a 30 year longitudinal study. Am J Psychiatry 158:1519–1520CrossRefPubMedGoogle Scholar
  41. Ramsey JD (2003) Personal CommunicationGoogle Scholar
  42. Ramsey JD, Butcher MA, Murphy MF, Lee T, Johnson A, Holt DW (2001) A new method to monitor drugs at dance venues. BMJ 232:603Google Scholar
  43. Renfroe CL (1986) MDMA on the street: analysis anonymous. J Psychoact Drugs 18:363–369Google Scholar
  44. Riley SCE, James C, Gregory D, Dingle H, Cadger M (2001) Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 96:1035–1047CrossRefPubMedGoogle Scholar
  45. Rodgers J (2000) Cognitive performance amongst recreational users of “ecstasy”. Psychopharmacology 151:19–24PubMedGoogle Scholar
  46. Saunders N (1995) Ecstasy and the dance culture. Neal’s Yard Desktop Publishing, LondonGoogle Scholar
  47. Schifano F (2000) Potential human neurotoxicity of MDMA (“ecstasy”): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33PubMedGoogle Scholar
  48. Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003) Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326:8–81CrossRefPubMedGoogle Scholar
  49. Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a www study. Addict Behav (in press)Google Scholar
  50. Sherlock K, Wolff K, Hay AWM, Conner M (1999) Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accident Emerg Med 16:194–197Google Scholar
  51. Shulgin AT, Nichols DE (1978) Characteristics of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The pharmacology of hallucinogens. Pergamon, New YorkGoogle Scholar
  52. Solowij N (1993) Ecstasy (3,4-methylenedioxymethamphetamine). Curr Opin Psychiatry 6:411–415Google Scholar
  53. Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87:1161–1172PubMedGoogle Scholar
  54. Spruit IP (2001) Monitoring synthetic drug markets, trends and public health. Subst Use Misuse 36:23–47CrossRefPubMedGoogle Scholar
  55. Steele TD, McCann UD, Ricaurte GA (1994) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:539–551PubMedGoogle Scholar
  56. Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55:105–115PubMedGoogle Scholar
  57. Wijngaart van de GM, Braam R, de Bruin D, Fris M, Maalste NJM, Verbraeck HT (1999) Ecstasy use at large scale dance events in the Netherlands. J Drug Issues 29:679–702Google Scholar
  58. Winstock AR, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64:9–17CrossRefPubMedGoogle Scholar
  59. World Health Organization (1996) Amphetamine like stimulants. Report from the WHO meeting on amphetamines, MDMA and other psychostimulants. November 1996. WHO, Geneva, SwitzerlandGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Department of PsychologyUniversity of Wales SwanseaSwansea Uited Kingdom

Personalised recommendations